Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Initial IND Warnings For CBD Supplements Could Ignite Regulatory Test

This article was originally published in The Tan Sheet

Executive Summary

FDA's warnings that supplements containing cannabis-derived ingredients are adulterated comes 10 months year after it stated the policy and a year after submitting other warnings that stopped short of saying the ingredients are noncompliant.


Related Content

It's Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims
CDB Supplements Next On FDA's Investigational New Drug Warning List
CBD Or Not To Be? ODI, NDI Or IND?
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
Omega-3 Drug Firm’s Trade Complaint Questions US Dietary Ingredient Standards


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts